Big Pharmas Explain Partnering Strategy At RESI On June 4th

By Lucy Parkinson, VP of Investor Research, LSN

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines.  RESI has become a venue for these major players to make connections with early stage biotech companies, and RESI includes a panel on Big Pharma to provide entrepreneurs with an opportunity to learn directly from experienced pharma scouts on how to find the right partner and get a deal made.

This panel will feature five speakers from various big pharma companies discussing topics such as:

  •     How does big pharma source these assets?
  •     How does the evaluation and investment process work?
  •     How can a startup position themselves to make a deal?
  •     What are some key factors that big pharma companies look for?
  •     How early stage is big pharma willing to look?

These panelists will shed some light on the process that big pharma goes through when sourcing early stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.

The panelists are:

  • Aaron Schwartz, Director, R&D Innovation Sourcing, Novo Nordisk
  • Brian Bronk, Head of External Innovation, Rare Diseases, Sanofi
  • Murali Gopalakrishnan, Sr. Director, Head Search & Evaluation Neuroscience, AbbVie
  • Nicola La Monica, Senior Director, Infectious Diseases and Vaccines Scientific Innovation, Johnson & Johnson Innovation, Boston
  • Yvonne Kobayashi, Sr Director, Emerging Technology & Innovation, Eli Lilly & Co

RESI Partnering Is Live: Book One-on-One Meetings For June 4th Now

By Lucy Parkinson, VP of Investor Research, LSN

On Monday June 4th, RESI will kick off Boston’s life science week with a full day of focused one-on-one partnering meetings, as well as panel and workshop content that covers the full nuances of early stage fundraising. With less than a month to go, RESI Partnering is now live, and it’s time to get your meeting requests out to these investors – and more. You can register online now

Confirmed Investors and Strategic Partners

As of May 7

At RESI, You Can Make New International Connections with Investors and Scientist Entrepreneurs

By Karen Deyo, Investor Research Analyst, LSN

Over a third of registered attendees for RESI on June 4th come from firms based outside the US. That’s an incredible audience for any early stage life science entrepreneur or investor who is looking to broaden their network and make new international connections in the global early stage life science world.

RESI’s international attendees include both startups and investors. With RESI’s afternoon track on Asia-North America Partners, LSN has seeded a venue where international connections can be made, and on June 4th RESI will be a source for both international investors and also global life science discoveries.

Life science startups from around the world have applied to the Innovation Challenge, representing countries such as Canada, France, Taiwan, and also including a large delegation from South Korea sponsored by KOTRA. Other startups attending RESI come from as far away as Australia, Argentina and Denmark.

The investors attending RESI are also from all around the world, including countries such as Malaysia, Japan and Germany. International attendees include family offices, venture capital firms, venture philanthropists and large strategic partners from across the word.
Attending RESI is a great way to meet and connect with the international life sciences community, both for companies looking to form relationships with investors and for investors looking to identify new and exciting technologies.

RESI 101: What Is RESI, What’s the Format, and Who Can You Meet There?

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The Redefining Early Stage Investments (RESI) Conference Series is an ongoing conference series of 5 events across North America for early stage life sciences companies to source investors, create relationships, and eventually, get funding.  If you’ve never been to RESI, there’s a lot to take in.  In this article we’ll cover who you can meet at RESI, what happens throughout the day, and how RESI’s format maximizes your chance of making connections.

The RESI conference focuses on the diverse breadth of early stage investors that Life Science Nation (LSN) tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

The RESI Partnering Forum allows fundraising executives to identify and book up to 16 meetings with life science investors who fit their company’s technology sector and stage of development. Because RESI is a pure partnering conference the “ad hoc” meeting component is critical as the conference is arranged so that it is easy to network and investors and strategic partners have red ribbons on their badges which facilitates introductions with the scientist-entrepreneurs and fundraising CEOs who are at RESI to meet them.

Attendees, through an expansive series of panels and workshops, have the chance to hear first-hand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.

Event format

RESI provides wrap around conference content, daylong matchmaking and networking. While the matchmaking focuses on 1 to 1 meetings and appointment setting, it is different than other similar investor events. No one is hosted. The companies that seek funding pay to attend. The investment organizations are invited to attend at no cost. As the partnering system will match the buyers and sellers together based on fit there is no guesswork as to who is selling to who which is a common problem at other events where partnering is an afterthought.

RESI Innovation Challenge: The Innovation Challenge takes place at every RESI conference and is a huge hit with early stage global investors seeking firms that align with their investment mandates. It was created for scientist-entrepreneur or fundraising CEOs starting to accumulate compelling proof-of-concept animal data or early stage clinical data. LSN has developed an expert system that facilitates the quick scoring and ranking of all of the companies and their technology assets that apply to get into the Innovation Challenge. A typical RESI conference gets over 100+ applications and LSN vets and ranks the top 30 applicants who present their technologies in an exhibition-style format throughout the full-day conference. Presenters gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5 to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors.

Attendees

Funding seekers – CEOs and senior executives from life science organizations, and scientist-entrepreneurs who have invented potentially valuable technology assets.

Investors – ten categories of early stage investors and strategic channel partnerships in life science or healthcare including

  • Investment staff involved directly in an early stage life science or healthcare venture capital or private equity fund.
  • Investment staff at a family office or private wealth fund that invests in life sciences.
  • External innovation, early stage partnering or in-licensing staff from major corporations in the lifescience and healthcare industry.
  • Active life science angels or executive staff at angel organizations that invest in early stage life science companies.
  • Investment staff and executives at nonprofit organizations, venture philanthropy/impact investment firms or patient groups that provide funding to startup companies.
  • Senior management or investment staff from a pension, endowment, foundation or employee benefit plan currently invested in life sciences.

Exhibitors

  • Scientific and technical service providers looking for early stage start-ups: CROs, CMOs.
  • Business service providers: accounting, consulting, law firms.
  • Regional life science organizations: incubators, accelerators, state government, bio-clusters.

Insights from Genomics Investors Panelists

By Jessica Yang, Investor Research Analyst, LSN

During RESI on MaRS – as part of Toronto Health Innovation Week – we invited five panelists from renowned investment groups focusing on genomics to share their insights. How do they assess the genomics-related areas of investment?

Moderated by Ihor Boszko, Vice President, Business Development, Ontario Genomics, the Genomics Investor Panelists were:

Here are some takeaway points from the panel discussion:

Tools, platforms, and technologies
Q: What do you see as exciting opportunities on the platforms/tools side of genomics? Is it in the decentralization of sequencing? Other genomics technologies?

  1. The key is to think about what kinds of applications and markets these companies are targeting. When investors look at new sequencing platforms, they are thinking about what differentiates these new technologies from centralized sequencing – what can these platforms do that centralized sequencing cannot? For innovative genomics companies, they must identify their target markets and specific applications they want to address in the decentralized models.
  2. From different angles, all points to the same direction – the guiding principle of making investments in the healthcare arena is looking for unique and differentiated technologies that address unmet needs. The other is costs, anything expanding access while lowering the cost speaks to investor’s interests. For example, platform technologies that make things cheaper, better, or faster, making it practical in clinical settings – this is what the investors are looking for.

Direct-to-consumer in Genomics

Q: What do you think about direct-to-consumer products in Genomics?

  1. More and more direct-to-consumer products come out on the market, and it’s getting easier for everyone to do it. However, genetics and genomics are complicated. In the current healthcare system, most people aren’t trained to order or interpret the results. The challenge is that training and sophistication will lag behind the technology for computers.

Some of these direct-to-consumer tasks are negatively impacting their reputation as it relates to quality. One of the ethics dilemmas around direct-to-consumer products is that people don’t understand the terms and conditions, and some of that is companies selling consumer data,

Hot Investor Mandate 4: Venture Arm of Large Korean Corporate Invests in Digital Health, with Increased Interests in Investment Opportunities in Biotech Therapeutics

A venture capital arm of a large Korean corporate has several offices in the USA. The firm has approximately has invested over $200M in 40 companies in the last year and invested $100M in 20 companies in 2016. The investment size greatly varies, depending on the opportunity. The firm is actively seeking new investment opportunities in the life sciences and will look globally.

The firm invests in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The firm is also interested in therapeutics, particularly synthetic biology, nanotechnology, and gene therapy. The firm is opportunistic in terms of stage of development.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI 2018 Investor Footprint

By Chris Cummings, Senior Marketing Manager, LSN

We are expecting significant international attendance at RESI Boston this June, due to its proximity to the BIO International Convention. Over 100 investors are already registered! The conference will be the third RESI of 2018, and is sure to continue matching early-stage investors with Biotech, Medtech, Diagnostics, and Digital Health startups. Check out some of the stats below to see what has happened so far at RESIs in 2018…


Click Here to See Investors